Impact of prior treatment on outcome of transformed @entity706 and relapsed de novo XXXX : a retrospective multicentre analysis.

@entity1 @entity1892 @entity706
UNASSIGNED: Transformation of @entity706 ( @entity706 ) into aggressive disease and relapse of de novo @entity1892 ( @entity1892 ) are considered highly unfavourable events. However, most published data were acquired when rituximab was not routinely used. We retrospectively analysed 50 @entity1 with transformed @entity706 (tFL) in a multicenter study and compared them to 50 individuals with relapsed @entity1892 (rDLBCL) who all obtained rituximab for the treatment of their disease. Our goal was to identify factors that predict a more favourable prognosis. After a median follow-up of 5.4  years from diagnosis, there was no significant difference in median overall survival (OS) from the date of transformation (tFL) or date of the first relapse (rDLBCL) (1.9 versus 3.9  years, P   =   .542). Of note, 5-year OS of @entity1 with tFL was 46  %. @entity706 @entity1 , treatment na  ve prior to transformation, fared significantly better than pretreated @entity1 (median not reached versus 1.4  years, P   =   .014). Regarding rDLBCL, female gender (13.9 versus 1.8  years, P   =   .019) and absence of rituximab prior to the first relapse (14.0 versus 1.8  years, P   =   .035) were favourable prognostic factors in a uni- and multivariate analysis. Only a proportion of @entity1 received high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT), i.e. 38 and 52  % of @entity1 with tFL and rDLBCL, respectively. Our data indicate that a favourable prognosis is conferred by treatment naivety in tFL and by rituximab naivety in rDLBCL. In contrast, we did not find a prognostic impact of HDT-ASCT in our series.
